PHASE I/II STUDY LADARIXIN AND SOTORASIB IN ADVANCED KRAS G12C MUTANT NON-SMALL CELL LUNG CANCER (NSCLC).

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Kras G12c Mutant Nsclc
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    To participate in the study the following conditions must be met:
    1. 1) A confirmed diagnosis of non-small cell lung cancer (NSCLC), which can be either squamous or nonsquamous type.
    2. 2) Cannot undergo surgery or radiation with the intention of curing their NSCLC
    3. 3) Tumor tissue must be tested and confirmed to have a specific mutation called KRASG12C.

You may not be eligible for this study if the following are true:

  • You will not be able to participate in the study if you have had:
    1. 1) Any blood cancers, except for stable chronic lymphocytic leukemia (CLL), within the last year
    2. 2) A known severe allergy to ladarixin, sotorasib, or any of the ingredients used to make these drugs.
    3. 3) Brain or spinal metastases, except if they have been treated with surgery or surgery plus radiotherapy or radiotherapy alone, and have not shown any signs of progression or bleeding for at least 7 days before starting treatment with the study drugs.



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.